Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 11, 2026, serves as a transaction notification for the month of May 2026. The document discloses a specific securities transaction involving a Principal Director or Manager (PDMR) rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide aggregate revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK plc. The only financial data present relates to a single insider transaction:
- Instrument: American Depositary Shares (ADS), ISIN: US37733W2044
- Transaction Price: $50.5000 per ADS
- Transaction Volume: 9.455 ADS
- Transaction Date: May 7, 2026
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records an acquisition of notional ADS within the GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine regulatory disclosure of an insider trading event.
Investor Verification Checklist
- Verify the identity of the PDMR: Maya Martinez-Davis, President, US.
- Confirm the transaction was an acquisition within an Executive Supplemental Savings Plan.
- Note that this filing does not contain quarterly or annual financial performance data.
- Check the LEI for GSK plc: 5493000HZTVUYLO1D793.